Feature | March 16, 2015

New Research Shows PCI Benefits STEMI Patients Even After 12 Hours

Late-presenting patients show same results as early presenters

Minneapolis Heart Institute Foundation, PCI, STEMI, late presenters

March 16, 2015 — New research from the Minneapolis Heart Institute Foundation (MHIF) finds that percutaneous coronary intervention for heart attacks can still be beneficial for patients who get to their more than 12 hours after their chest pain has started. Timothy Henry, M.D., lead MHIF researcher and director of cardiology at Cedars-Sinai Medical Center in Los Angeles, presented the study results at the 2015 American College of Cardiology (ACC) conference in San Diego.

Almost 250,000 Americans experience ST-elevated myocardial infarction (STEMI), the deadliest form of heart attack, each year. Many of these patients are treated with percutaneous coronary intervention (PCI, or coronary artery stenting) within 90 minutes of getting to a medical center — a guideline recommended by the American Heart Association. But treatment guidelines have been less clear for patients who get to a medical center late — more than 12 hours after their chest pain has started. “Despite previous studies showing PCI improves survival for these late presenters,” said Henry, “management of these patients continues to be controversial.”

To further study the impact of PCI on STEMI patients who receive later treatment, Henry and a team of MHIF researchers examined prospective data from 3,157 patients in the Level 1 regional STEMI program at the Minneapolis Heart Institute at Abbott Northwestern Hospital from March 2003 to March 2014. They placed the patients into three groups: those that arrived at a medical center within 6 hours of chest pain starting (“early presenters”), those arriving within 6–12 hours, and those arriving 12–24 hours after the start of pain (“late presenters”).

The death rate (in-hospital, at 30 days, and at 1 year) and length of hospital stay for late presenters (6.7 percent of patients) was similar to that of early presenters. “Our research supports the use of primary PCI in late presenters,” stated Henry. “Although the door to balloon time was longer for late presenters, the clinical benefits of PCI were similar to those who received earlier treatment.”

For more information: www.mplsheart.org


Related Content

News | Cardiovascular Clinical Studies

April 24, 2024 —Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
Subscribe Now